PL2268310T3 - Use of a type ii anti-cd20 antibody with increased antibody dependent cellular cytotoxicity (adcc) in combination with cyclophosphamide, vincristine and doxorubicine for treating non-hodgkin' s lymphomas - Google Patents
Use of a type ii anti-cd20 antibody with increased antibody dependent cellular cytotoxicity (adcc) in combination with cyclophosphamide, vincristine and doxorubicine for treating non-hodgkin' s lymphomasInfo
- Publication number
- PL2268310T3 PL2268310T3 PL09723808T PL09723808T PL2268310T3 PL 2268310 T3 PL2268310 T3 PL 2268310T3 PL 09723808 T PL09723808 T PL 09723808T PL 09723808 T PL09723808 T PL 09723808T PL 2268310 T3 PL2268310 T3 PL 2268310T3
- Authority
- PL
- Poland
- Prior art keywords
- antibody
- doxorubicine
- adcc
- lymphomas
- vincristine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/664—Amides of phosphorus acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08005554 | 2008-03-25 | ||
EP08007172 | 2008-04-11 | ||
EP09723808.3A EP2268310B1 (en) | 2008-03-25 | 2009-03-23 | Use of a type ii anti-cd20 antibody with increased antibody dependent cellular cytotoxicity (adcc) in combination with cyclophosphamide, vincristine and doxorubicine for treating non-hodgkin' s lymphomas |
Publications (1)
Publication Number | Publication Date |
---|---|
PL2268310T3 true PL2268310T3 (en) | 2017-08-31 |
Family
ID=40872445
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL09723808T PL2268310T3 (en) | 2008-03-25 | 2009-03-23 | Use of a type ii anti-cd20 antibody with increased antibody dependent cellular cytotoxicity (adcc) in combination with cyclophosphamide, vincristine and doxorubicine for treating non-hodgkin' s lymphomas |
Country Status (31)
Country | Link |
---|---|
US (6) | US20090246197A1 (en) |
EP (1) | EP2268310B1 (en) |
JP (3) | JP5547709B2 (en) |
KR (1) | KR101280716B1 (en) |
CN (2) | CN101983071A (en) |
AR (1) | AR072947A1 (en) |
AU (1) | AU2009228616B2 (en) |
BR (1) | BRPI0909227B8 (en) |
CA (1) | CA2716884C (en) |
CL (1) | CL2009000713A1 (en) |
CR (1) | CR11687A (en) |
CY (1) | CY1117984T1 (en) |
DK (1) | DK2268310T3 (en) |
ES (1) | ES2592312T3 (en) |
HR (1) | HRP20161301T1 (en) |
HU (1) | HUE028828T2 (en) |
IL (1) | IL208018A (en) |
LT (1) | LT2268310T (en) |
MA (1) | MA32140B1 (en) |
MX (1) | MX2010009647A (en) |
MY (1) | MY163544A (en) |
NZ (1) | NZ587284A (en) |
PE (1) | PE20091821A1 (en) |
PL (1) | PL2268310T3 (en) |
PT (1) | PT2268310T (en) |
RS (1) | RS55258B1 (en) |
RU (1) | RU2589704C2 (en) |
SI (1) | SI2268310T1 (en) |
TW (1) | TWI500624B (en) |
WO (1) | WO2009118142A1 (en) |
ZA (1) | ZA201006190B (en) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RS57466B1 (en) | 2003-11-05 | 2018-09-28 | Roche Glycart Ag | Antigen binding molecules with increased fc receptor binding affinity and effector function |
CL2009000713A1 (en) * | 2008-03-25 | 2010-04-09 | Hoffmann La Roche | Pharmaceutical composition comprising an anti-cd20 type II antibody with increased antibody-dependent cellular cytotoxicity (ccda) and one or more chemotherapeutic agents; and its use to treat a cancer that expresses cd20. |
AR073295A1 (en) | 2008-09-16 | 2010-10-28 | Genentech Inc | METHODS TO TREAT PROGRESSIVE MULTIPLE SCLEROSIS. MANUFACTURING ARTICLE. |
AR078161A1 (en) | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | VERY CONCENTRATED PHARMACEUTICAL FORMULATIONS OF AN ANTIBODY ANTI CD20. USE OF THE FORMULATION. TREATMENT METHOD |
CA3154024C (en) | 2010-06-03 | 2024-02-27 | Pharmacyclics Llc | Use of inhibitors of bruton's tyrosine kinase (btk) in the treatment of relapsed or refractory follicular lymphoma |
MX2013006739A (en) * | 2010-12-16 | 2013-07-17 | Roche Glycart Ag | Combination therapy of an afucosylated cd20 antibody with a mdm2 inhibitor. |
US20130302274A1 (en) * | 2011-11-25 | 2013-11-14 | Roche Glycart Ag | Combination therapy |
MX2015001081A (en) | 2012-07-24 | 2015-10-14 | Pharmacyclics Inc | Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk). |
SG11201604875PA (en) * | 2013-12-17 | 2016-07-28 | Genentech Inc | Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody |
US9732154B2 (en) | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
US9603927B2 (en) * | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
MX2017003115A (en) | 2014-09-09 | 2017-11-17 | Janssen Biotech Inc | Combination therapies with anti-cd38 antibodies. |
CN107406506A (en) | 2014-12-04 | 2017-11-28 | 詹森生物科技公司 | For treating the antibody of AntiCD3 McAb 8 of acute myeloid leukemia |
JP6827426B2 (en) | 2015-05-20 | 2021-02-10 | ヤンセン バイオテツク,インコーポレーテツド | Anti-CD38 antibody for the treatment of light chain amyloidosis and other CD38-positive hematological malignancies |
AU2016282674B2 (en) | 2015-06-22 | 2022-01-13 | Janssen Biotech, Inc. | Combination therapies for heme malignancies with anti-CD38 antibodies and survivin inhibitors |
US20170044265A1 (en) | 2015-06-24 | 2017-02-16 | Janssen Biotech, Inc. | Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38 |
US10781261B2 (en) | 2015-11-03 | 2020-09-22 | Janssen Biotech, Inc. | Subcutaneous formulations of anti-CD38 antibodies and their uses |
LT3827845T (en) | 2015-11-03 | 2022-06-10 | Janssen Biotech, Inc. | Subcutaneous formulations of anti-cd38 antibodies and their uses |
CA3007997A1 (en) * | 2015-12-10 | 2017-06-15 | City Of Hope | Cell penetrating cyanine-coupled antibodies |
BR112019006781A2 (en) | 2016-10-07 | 2019-07-30 | Novartis Ag | chimeric antigen receptors for cancer treatment |
WO2018106931A1 (en) | 2016-12-07 | 2018-06-14 | Progenity Inc. | Gastrointestinal tract detection methods, devices and systems |
EP4108183A1 (en) | 2017-03-30 | 2022-12-28 | Biora Therapeutics, Inc. | Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device |
US11618787B2 (en) | 2017-10-31 | 2023-04-04 | Janssen Biotech, Inc. | Methods of treating high risk multiple myeloma |
WO2019246317A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease or condition in a tissue originating from the endoderm |
US20230041197A1 (en) | 2018-06-20 | 2023-02-09 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immunomodulator |
WO2020106757A1 (en) | 2018-11-19 | 2020-05-28 | Progenity, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
AR122307A1 (en) * | 2019-10-04 | 2022-08-31 | Chugai Pharmaceutical Co Ltd | OBINUTUZUMAB TOLERANT CD20 POSITIVE CANCER CELL PROLIFERATION SUPPRESSION AGENT, AND PHARMACEUTICAL COMPOSITION, DRUG, MANUFACTURING, CELL PROLIFERATION SUPPRESSION METHOD, TREATMENT METHOD, TYPE II ANTI-CD20 ANTIBODY, COMPOUND, THEIR COMBINATIONS, AND AGENT ENHANCER AND INDUCING AGENT, RELATED TO THESE |
EP3870261B1 (en) | 2019-12-13 | 2024-01-31 | Biora Therapeutics, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US5736137A (en) * | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
DK2180007T4 (en) * | 1998-04-20 | 2017-11-27 | Roche Glycart Ag | Glycosylation technique for antibodies to enhance antibody-dependent cell cytotoxicity |
RU2306952C2 (en) * | 2001-01-31 | 2007-09-27 | Байоджен Айдек Инк. | Method for treating the cases of malignant tumors containing b-cells with a combination of applications related to antibodies reducing b-cells number and with immunomodulating antibodies |
NZ581541A (en) * | 2002-10-17 | 2011-07-29 | Genmab As | Human monoclonal antibodies against CD20 |
JP4351674B2 (en) * | 2002-12-16 | 2009-10-28 | ジェネンテック・インコーポレーテッド | Immunoglobulin variants and their use and use |
RS57466B1 (en) * | 2003-11-05 | 2018-09-28 | Roche Glycart Ag | Antigen binding molecules with increased fc receptor binding affinity and effector function |
DOP2006000029A (en) * | 2005-02-07 | 2006-08-15 | Genentech Inc | ANTIBODY VARIANTS AND USES THEREOF. (VARIATIONS OF AN ANTIBODY AND USES OF THE SAME) |
KR20080031001A (en) * | 2005-06-02 | 2008-04-07 | 아스트라제네카 아베 | Antibodies directed to cd20 and uses thereof |
CN101291954B (en) * | 2005-08-26 | 2013-03-27 | 罗氏格黎卡特股份公司 | Modified antigen binding molecules with altered cell signaling activity |
WO2009030368A1 (en) * | 2007-09-05 | 2009-03-12 | F. Hoffmann-La Roche Ag | Combination therapy with type i and type ii anti-cd20 antibodies |
CL2009000713A1 (en) * | 2008-03-25 | 2010-04-09 | Hoffmann La Roche | Pharmaceutical composition comprising an anti-cd20 type II antibody with increased antibody-dependent cellular cytotoxicity (ccda) and one or more chemotherapeutic agents; and its use to treat a cancer that expresses cd20. |
-
2009
- 2009-03-23 CL CL2009000713A patent/CL2009000713A1/en unknown
- 2009-03-23 DK DK09723808.3T patent/DK2268310T3/en active
- 2009-03-23 WO PCT/EP2009/002111 patent/WO2009118142A1/en active Application Filing
- 2009-03-23 CA CA2716884A patent/CA2716884C/en active Active
- 2009-03-23 PL PL09723808T patent/PL2268310T3/en unknown
- 2009-03-23 JP JP2011501133A patent/JP5547709B2/en active Active
- 2009-03-23 TW TW098109412A patent/TWI500624B/en active
- 2009-03-23 MY MYPI2010004461A patent/MY163544A/en unknown
- 2009-03-23 CN CN2009801101810A patent/CN101983071A/en active Pending
- 2009-03-23 ES ES09723808.3T patent/ES2592312T3/en active Active
- 2009-03-23 KR KR1020107021332A patent/KR101280716B1/en active IP Right Grant
- 2009-03-23 LT LTEP09723808.3T patent/LT2268310T/en unknown
- 2009-03-23 HU HUE09723808A patent/HUE028828T2/en unknown
- 2009-03-23 RS RS20160864A patent/RS55258B1/en unknown
- 2009-03-23 MX MX2010009647A patent/MX2010009647A/en active IP Right Grant
- 2009-03-23 AU AU2009228616A patent/AU2009228616B2/en active Active
- 2009-03-23 NZ NZ587284A patent/NZ587284A/en unknown
- 2009-03-23 US US12/408,746 patent/US20090246197A1/en not_active Abandoned
- 2009-03-23 SI SI200931530A patent/SI2268310T1/en unknown
- 2009-03-23 AR ARP090101035A patent/AR072947A1/en unknown
- 2009-03-23 EP EP09723808.3A patent/EP2268310B1/en active Active
- 2009-03-23 RU RU2010143454/15A patent/RU2589704C2/en active
- 2009-03-23 BR BRPI0909227A patent/BRPI0909227B8/en active IP Right Grant
- 2009-03-23 CN CN201611215290.7A patent/CN107198772A/en active Pending
- 2009-03-23 PT PT97238083T patent/PT2268310T/en unknown
- 2009-03-24 PE PE2009000437A patent/PE20091821A1/en not_active Application Discontinuation
-
2010
- 2010-05-10 US US12/777,141 patent/US20100310581A1/en not_active Abandoned
- 2010-08-30 ZA ZA2010/06190A patent/ZA201006190B/en unknown
- 2010-09-03 MA MA33145A patent/MA32140B1/en unknown
- 2010-09-06 IL IL208018A patent/IL208018A/en active IP Right Grant
- 2010-09-23 CR CR11687A patent/CR11687A/en unknown
-
2011
- 2011-03-07 US US13/042,305 patent/US20110177067A1/en not_active Abandoned
- 2011-10-28 US US13/284,415 patent/US20120301459A1/en not_active Abandoned
-
2013
- 2013-03-14 US US13/829,409 patent/US20140065134A1/en not_active Abandoned
-
2014
- 2014-01-24 JP JP2014011332A patent/JP5912142B2/en active Active
- 2014-06-05 US US14/297,478 patent/US20160000911A1/en not_active Abandoned
-
2016
- 2016-03-18 JP JP2016055096A patent/JP6154039B2/en active Active
- 2016-09-07 CY CY20161100889T patent/CY1117984T1/en unknown
- 2016-10-10 HR HRP20161301TT patent/HRP20161301T1/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL208018A0 (en) | Use of a type ii anti-cd20 antibody with increased antibody dependent cellular cytotoxicity (adcc) in combination with cyclophosphamide, vincristine and doxorubicine for treating non-hodgkin's lymphomas | |
IL254498B (en) | Peptidomimetic macrocycle composition for use in treating disease | |
ZA201002773B (en) | Porcine dc-sign,icam-3 and lsectin and uses thereof | |
EP2377897A4 (en) | Absorbing resin particles, process for producing same, and absorbent and absorbing article both including same | |
EP1984175A4 (en) | Multilayer material, method for making same and use as electrode | |
EP2299957A4 (en) | Collection pouches in absorbent articles | |
IL200905A0 (en) | Compounds and compositions comprising the same for use in treating hepatitis c | |
ZA200802274B (en) | Absorbent article with improved garment-like character | |
EP2367665A4 (en) | Composition and method for treating wood-based material and wood-based material treated with the composition | |
EP2177506A4 (en) | Positive resist composition, pattern forming method using the composition, and compound used in the composition | |
EP2371904A4 (en) | Near-infrared-ray absorbing material containing cyanine compound, and cyanine compound | |
HUE046349T2 (en) | Composition for treating cancer cells and synthetic method for the same | |
ZA200903771B (en) | Carbamate compounds for use in treating depression | |
EP1952811A4 (en) | The use of eriocalyxin b in the manufacture of medicaments for treating leukemia | |
EP2213386A4 (en) | Method for washing soil containing cyanogen compound, and microorganism for use in the washing method | |
GB2435262B (en) | Method, composition and articles | |
EP2085061A4 (en) | Process for producing absorbent article, and absorbent article | |
PL2110241T3 (en) | Compound material, in particular for highly extendable and semi-elastic closing elements on nappies | |
GB2450812B (en) | Compound, ink, process and use | |
GB0708531D0 (en) | Process, compound, ink and use | |
GB0612029D0 (en) | Compound, ink, process and use | |
EP2007838A4 (en) | Near-infrared absorbing material | |
GB0620089D0 (en) | Process, composition and ink | |
ZA200902612B (en) | Rubber composition for belt and rubber belt | |
EP2150243A4 (en) | Compositions and methods for enhancing active agent absorption |